智飞生物：关于CA111注射液获得临床试验批准通知书的公告

Core Viewpoint - The company, Zhifei Biological, has received approval from the National Medical Products Administration for clinical trials of its CA111 injection in overweight or obese adult patients [1] Group 1 - Zhifei Biological announced that its subsidiary, Chongqing Chen'an Biopharmaceutical Co., Ltd., has developed the CA111 injection [1] - The approval notification for the clinical trial is identified by the numbers 2025LP02405 and 2025LP02406 [1] - The clinical trials will focus on adult patients who are overweight or obese [1]